drugset / Trial / NCT02257788
PRO 140 for Human Immunodeficiency Virus Infection
Phase 2
Withdrawn
Drexel University
National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
PRO 140 2103 is a multicenter, randomized parallel group study, conducted in male and female adult subjects infected with CCR5-tropic HIV-1.
Timeline
- Start
- 2014-09
- Primary completion
- 2015-02
- Completion
- 2015-02
Outcome
Outcome not reported
Stopped (Enrollment): “Unlikely to achieve targeted accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Leronlimab | Monoclonal antibody | 350 mg | Subcutaneous |
| Comparator | Leronlimab | Monoclonal antibody | 700 mg | Subcutaneous |